B+
Bull case
15%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
CMMB
Chemomab TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Nebokitug retains substantial clinical and partnering optionality. SPRING-derived biomarker analyses support the proposed mechanism, and a funded Phase 3 path or strategic partner could create substantial upside from the current microcap valuation [#PR-EARNINGS-2026-05-14].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Clinical biomarker and translational findings are not proof of future Phase 3 efficacy or approval.
Momentum
84
Value
41
Sentiment
9
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.25 · Bull $4.00 · Bear $0.55Analysis 2026-07-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum84 · Δ7d -
Value41 · Δ7d -0.0
Sentiment9 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Clinical biomarker and translational findings are not proof of future Phase 3 efficacy or approval.
- • Coverage is low, peers are loose, and the packet contains no verified post-print analyst revisions or market-reaction attribution.
- • The company remains dependent on future capital or a partner to advance Phase 3.
Catalyst clock
2026-08-31
Liquidity runway provides a temporary floor
Lead driver: Value · See fundamentals
Momentum
84
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
9
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 83.8 / Value 41.2 / Sentiment 8.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-25. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-07-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$13.83M
Beta
0.55
Shares Out
7.2M
P/E (TTM) · Derived
-1.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.23
Rev YoY
-
EPS YoY
-24.2%
Gross Margin
-
Op Margin
-
Net Debt
-$10.37M
Current Ratio
6.41
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data